Akoya Biosciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
SCHEDULE 13D/A: Akoya Biosciences Terminates Quanterix Voting Agreement Following Amended Merger Deal
Akoya Biosciences, Inc. has terminated its Voting and Support Agreement with certain Quanterix Corp. stockholders, a procedural step following the execution of an Amended and Restated Agreement and Plan of Merger.
SCHEDULE 13D/A: Quanterix Amends Akoya Biosciences Merger Agreement, Securing Majority Shareholder Support
Quanterix Corporation has amended its merger agreement with Akoya Biosciences, Inc., outlining revised acquisition terms and securing voting support from key Akoya shareholders representing 55.6% of outstanding common stock.
SCHEDULE 13D: Quanterix Corporation to Acquire Akoya Biosciences in Strategic Merger, Reshaping Single-Cell Imaging Landscape
Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. through a merger, with Akoya becoming a wholly-owned subsidiary of Quanterix, significantly altering the combined entity's ownership structure and board composition.
SCHEDULE 13D: Quanterix to Acquire Akoya Biosciences in All-Stock Merger Valued at 0.318 Shares Per Akoya Stock
Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. in an all-stock transaction, with Akoya becoming a wholly-owned subsidiary of Quanterix.